ArticleBioMed research international2019
Carbapenem-Resistant
Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Pooled it
- Temporal Trends in Antibiotic Resistance of Klebsiella pneumoniae and Antibiotic Consumption: A Six-year Longitudinal Surveillance Study : Temporal Trends of Resistance and Consumption of Antibiotics to K. pneumoniae.Journal of epidemiology and global health · 2026Article
- Prognostic factors for mortality in critically ill patients with infections caused by carbapenem-resistant gram-negative pathogens treated with ceftazidime-avibactam: a multicenter retrospective study.BMC infectious diseases · 2026Article
- Detection and distribution of carbapenemase-encoding genes in clinicalIranian journal of microbiology · 2026Article
- Editorial: Advances in combating antimicrobial resistance: focus on diagnosis, therapy, and prevention.Frontiers in cellular and infection microbiology · 2026Article
- Interpretable machine learning for early detection of carbapenem-resistantFrontiers in public health · 2026Article
- Drug Resistance and Epidemiological Analysis of Carbapenem-Resistant Enterobacteriaceae in a Brain and Psychiatric Hospital of South China.Journal of clinical laboratory analysis · 2025Article
- Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.Scientific reports · 2025Article
- Evolution of ceftazidime-avibactam resistance driven by variation inFrontiers in cellular and infection microbiology · 2025Article
- Editorial: Infections in the intensive care unit, volume II.Frontiers in medicine · 2025Article
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Genomic study substantiates the intensive care unit as a reservoir for carbapenem-resistantMicrobial genomics · 2024Article
- Development and validation of machine learning models to predict MDRO colonization or infection on ICU admission by using electronic health record data.Antimicrobial resistance and infection control · 2024Article
- Genomic and immunocyte characterisation of bloodstream infection caused by Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2024Article
- Solithromycin in Combination with Other Antimicrobial Agents Against the Carbapenem ResistantIndian journal of microbiology · 2024Article
- Carbapenem-resistant gram-negative bacterial infections and risk factors for acquisition in a Kenyan intensive care unit.BMC infectious diseases · 2024Article
- The Global and Regional Prevalence of Hospital-Acquired Carbapenem-ResistantOpen forum infectious diseases · 2024Review
- Development and application of a nomogram model for the prediction of carbapenem-resistantMicrobiology spectrum · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prevalence of infections due to carbapenem-resistant
methodsFive hundred and seven consecutive ICU admission patients with
resultsOf the total 507 isolates of KP, 244 (48.1%) strains were carbapenem resistant. The majority of these isolates were from sputum (30.9%) and blood (20.9%) samples. Tigecycline had good activity against CRKP (95.5%). The most common sequence type (ST) of CRKP was ST11 (84.4%), and 98.6% of them had the
conclusionsST11 carrying the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.